Over the past few years we have talked a lot about the promise of gene therapy – treatments designed for a specific gene, like Luxturna for RPE56. There is growing interest now in therapies that are not designed for a specific gene – but instead may be able to treat many mutations causing at disease. These potential treatments are called gene agnostic therapies.

In this webinar, join us for a conversation with Dr. Daniel Chung, chief medical officer at SparingVision, which is developing a gene-agnostic therapy to preserve cone vision in people with retinitis pigmentosa, Usher syndrome, and related conditions.